Multiple Sclerosis — Written Clinical Reasoning

Part A — Diagnosis and disease activity assessment

Diagnosis

The diagnosis of relapsing-remitting multiple sclerosis is established, meeting the McDonald 2017 criteria. Dissemination in space is demonstrated by lesions in three of the four characteristic locations (periventricular, juxtacortical, and infratentorial — only two are required). Dissemination in time is demonstrated by the simultaneous presence of gadolinium-enhancing (acute) and non-enhancing (older) lesions on the current MRI [1]. The diagnosis is further supported by the clinical history of four discrete relapses separated by periods of remission, with incomplete recovery indicating accumulating disability.

Disease activity and severity

This patient has highly active disease despite first-line DMT (interferon beta-1a). The indicators of high activity and poor prognosis are: four relapses in 18 months (annualised relapse rate of approximately 2.7, well above the untreated rate of 0.5 to 1 per year), incomplete recovery from recent relapses with residual deficit (left leg weakness and a sensory level), and a high MRI lesion burden with active gadolinium-enhancing lesions. This patient meets the criteria for DMT escalation to a high-efficacy agent. [1]

Exclusion of mimics

Before escalating therapy, I would confirm that the diagnosis is truly MS and not a mimic. The key test is serum AQP4-IgG and MOG-IgG to exclude neuromyelitis optica spectrum disorder and MOG-antibody disease — both of which can present with relapsing optic neuritis and transverse myelitis but require completely different treatment. The presence of CSF oligoclonal bands (if available) would further support MS, but their absence does not exclude it. I would also check B12, TSH, ANA, and ACE to exclude metabolic, autoimmune, and sarcoid mimics [1].

Part B — DMT escalation strategy and risk-benefit analysis

Principles

The patient has highly active RRMS that has failed interferon beta-1a. The modern approach is to escalate to a high-efficacy DMT to achieve no evidence of disease activity (NEDA) and prevent further disability accumulation. The candidate agents, in order of consideration, are: [1]

Option 1 — Natalizumab

Natalizumab (300 mg IV every 4 weeks) is one of the most effective DMTs for RRMS, reducing relapse rate by approximately 68 per cent. However, this patient is JC virus antibody positive, which carries a risk of progressive multifocal leukoencephalopathy (PML). With no prior immunosuppression, the risk after 24 months of treatment is approximately 1 to 2 per 1000, rising with treatment duration and JCV index [7]. The JCV index should be quantified to further stratify risk. If the index is high (above 1.5), the risk is higher, and an alternative agent may be preferred. If natalizumab is chosen, MRI surveillance every 3 to 4 months is required to detect PML early (subtle new lesions on FLAIR and diffusion-weighted imaging, often in the frontal or parietal regions before clinical symptoms).

Option 2 — Ocrelizumab

Ocrelizumab (600 mg IV every 6 months) is an anti-CD20 monoclonal antibody that depletes B cells. It has no PML risk (unlike natalizumab), and the OPERA trials demonstrated superior efficacy to interferon beta-1a in RRMS (46 to 47 per cent reduction in annualised relapse rate and 40 per cent reduction in disability progression) [5]. Pre-treatment screening includes hepatitis B surface antigen and core antibody (reactivation risk), hepatitis C, quantiferon, and immunoglobulin levels. The main risks are infusion reactions (managed with premedication), infections, and a possible signal for malignancy (breast cancer in the trials) requiring ongoing surveillance. Given the patient is JCV-positive, ocrelizumab is an attractive alternative to natalizumab with comparable efficacy and no PML risk.

Option 3 — Alemtuzumab

Alemtuzumab (12 mg IV daily for 5 days, then 3 days 12 months later) has very high efficacy but carries a significant risk of secondary autoimmunity — thyroid disease in approximately 30 per cent, immune thrombocytopenia in approximately 2 per cent, and Goodpasture syndrome in less than 1 per cent — requiring monthly blood monitoring (CBC, creatinine, urinalysis) for 48 months [3]. Given the availability of ocrelizumab (which has a more favourable safety profile and simpler monitoring), alemtuzumab is reserved for patients who have failed or cannot tolerate other high-efficacy agents.

Recommendation

My recommendation is ocrelizumab — it offers high efficacy comparable to natalizumab without the PML risk that is particularly relevant in this JCV-positive patient, has a convenient 6-monthly infusion schedule, and does not require the monthly blood monitoring of alemtuzumab. If the patient declines infusion therapy or prefers an oral agent, cladribine (3.5 mg per kg total over 2 years in 2 annual courses) or dimethyl fumarate (240 mg twice daily with CBC monitoring) are reasonable alternatives. [1]

Part C — Monitoring plan

Disease activity monitoring

• Clinical review every 3 to 6 months — assess for relapses (new neurological symptoms lasting more than 24 hours, separated from the last episode by at least 30 days), disability progression (EDSS), and treatment adherence.
• MRI brain and cervical spine with gadolinium at 6 to 12 months after starting the new DMT, then annually, to assess for new or enhancing lesions (NEDA target: no relapses, no new MRI lesions, no disability progression) [2].
• If on natalizumab: MRI every 3 to 4 months for PML surveillance.

Drug-specific monitoring

• Ocrelizumab: pre-infusion CBC, liver function, and infection screen; hepatitis B and C screening and quantiferon before each infusion cycle; observation for infusion reactions during the infusion (premedicate with methylprednisolone, antihistamine, and paracetamol).
• If on dimethyl fumarate: CBC every 3 months for the first 6 months, then every 6 to 12 months (monitor for lymphopenia — PML risk with severe prolonged lymphopenia).
• If on fingolimod: baseline ECG, first-dose 6-hour cardiac monitoring, ophthalmology review at 3 to 4 months (macular oedema), CBC and liver function. [1]

Part D — Acute relapse management

For any future relapse causing functional impairment:

• First-line: methylprednisolone 1 g IV daily for 3 to 5 days (or 500 mg orally daily for 5 days — non-inferior in most studies). Gastroprotection with a PPI, and bone protection with calcium and vitamin D. Monitor blood glucose.
• Second-line for steroid-refractory severe relapses: plasma exchange, 5 to 7 exchanges over approximately 2 weeks. Do not repeat steroid courses for a relapse that has already failed steroids.
• Mild sensory relapses without functional impairment can be managed expectantly without steroids.
• If relapses continue despite the new high-efficacy DMT, reconsider the diagnosis (is it truly MS, or NMOSD/MOGAD?), assess adherence, and consider switching to an alternative agent. [1]

Part E — Symptom management

The patient has residual left leg weakness and a T10 sensory level, suggesting spinal cord involvement. Symptom management should address:

• Spasticity: physiotherapy and stretching first; oral baclofen (5 mg three times daily, titrate to 80 mg daily) or tizanidine; botulinum toxin for focal spasticity; intrathecal baclofen for severe generalised spasticity.
• Bladder dysfunction: check post-void residual; if detrusor overactivity (urgency, frequency), anticholinergics (oxybutynin, solifenacin) or mirabegron; if retention (high residual), intermittent self-catheterisation; urodynamic studies for mixed patterns.
• Fatigue: rule out anaemia, sleep apnoea, depression, vitamin D deficiency; amantadine 100 mg twice daily; energy conservation and graded exercise.
• Neuropathic pain: gabapentin, pregabalin, or amitriptyline (use with caution if bladder dysfunction — anticholinergic effects worsen retention).
• Depression: screen with PHQ-9 at each visit; SSRIs (sertraline, escitalopram) first-line; psychological support.
• Vitamin D supplementation: target serum 25-OH vitamin D above 75 nmol per litre; typically 1000 to 2000 IU daily. [1]

Part F — Reproductive planning

The patient plans to start a family within 2 years. This requires careful DMT planning [8]:

Current DMT and pregnancy

• Ocrelizumab (if chosen): depletes B cells for 6 to 12 months after the last dose. Discontinue 6 to 12 months before conception. If pregnancy occurs sooner, the drug has already been administered and B-cell depletion will persist — the neonate should be monitored for B-cell depletion and live vaccines deferred.
• Natalizumab (if chosen): may be continued through pregnancy in patients with highly active disease (stopping risks severe rebound relapses). If stopped, restart promptly postpartum.
• Dimethyl fumarate (if chosen): discontinue 1 month before conception.
• Cladribine (if chosen): discontinue 6 months before conception.

Safe DMT in pregnancy

If ongoing DMT is needed during pregnancy, glatiramer acetate is the preferred option (category B — no evidence of teratogenicity) and can be continued throughout pregnancy and breastfeeding.

Pregnancy and postpartum counselling

The PRIMS study (Confavreux 1998) established that relapse rate drops during pregnancy (lowest in the third trimester) and rises in the first 3 months postpartum (annualised rate 1.2 versus 0.7 pre-pregnancy) [8]. However, 72 per cent of women do not experience a postpartum relapse. Breastfeeding may be protective — if the patient chooses to breastfeed exclusively, DMTs are withheld (except glatiramer), and the DMT is restarted promptly after weaning. Epidural analgesia is safe and does not affect relapse rate. The patient should be counselled that MS does not affect fertility, and pregnancy does not worsen long-term disability. Vitamin D supplementation should continue throughout pregnancy. A plan for postpartum DMT restart should be agreed before delivery to avoid the high-risk postpartum window.

Part G — Excluding the mimics before locking in the diagnosis

Before committing this patient to lifelong high-efficacy DMT, I would actively exclude NMOSD and MOGAD. The clinical picture — relapsing optic neuritis and transverse myelitis with incomplete recovery — is compatible with both MS and NMOSD. The key distinguishing features are: MS myelitis is short (less than 2 segments) and partial, while NMOSD myelitis is longitudinally extensive (more than 3 segments); MS optic neuritis is unilateral with good recovery, while NMOSD optic neuritis is often bilateral, severe, and poorly recovered. The presence of periventricular, juxtacortical, and infratentorial brain lesions and the oligoclonal band pattern favour MS. But AQP4-IgG must be checked, because if positive, the entire management changes — natalizumab, interferon, and glatiramer may be harmful, and the patient would need rituximab, mycophenolate, or azathioprine [1].